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he United States has the highest per capita expenditure for medical care in
the world.1 This is very likely due in part to the greater per capita delivery
of new expensive high technology in medicine. The delivery of medical care
n the United States is addressed through a profound and increasing redistribution
f wealth. In 2003, 46% of our $1.68 trillion health bill was paid by public funds
32% federal, 13% state and local) and only 54% from private funds (private
ealth insurance, out-of-pocket payments).2 The delivery system must be held
ccountable for these societal costs and keep track of the value it adds to the
merican economy. This financial stewardship must be added to our long-term
ollow-up systems.
Cardiothoracic surgery has been a pioneer in accurate reporting of long-term
esults using prospective systems with aggressive follow-up on a regular basis.
hrough our national organizations, we surgeons have developed guidelines and
tandards that allow useful comparisons. To fulfill this work, we must now add
nformation concerning costs and economic value.
The number of articles published on cost-benefit analysis has increased enor-
ously in just the past few years, but the medical costs thus identified provide only
part of the economic picture. Cost-effectiveness ratios (CER) do not address the
conomic value of the intervention under study. The actual cost would determine the
alue in a free market system. However, in the vast majority of medical transactions
 free market system does not operate1 and an administrative pricing system
revails.
The end product of a cost-effectiveness analysis in the medical domain, the CER
or a new or proposed therapy, is the incremental dollars needed to “produce” one
ncremental (quality-adjusted) life-year. After this number is determined, it is
ompared with somewhat arbitrary thresholds: less than $20K is considered very
ost-effective, $20K to 50K is probably cost-effective, and greater than $100K is not
ost-effective. The vagueness of these cut points derives from our reluctance or
nability to put a price on a year of life.
Under these circumstances, however, it is possible to look to other areas of the
conomy, where market forces do operate to determine the economic value of a
ife-year and the value of a statistical life (VSL), and to use these determinations in
ur economic value calculations. Fortunately, economists have addressed these
ssues, and their methods of analysis are now ready for medical use. Thus, a great
eparture from the usual cost-effectiveness analysis, which ends with the cost of
roducing a life-year, is to use these innovative econometric methods to put a
alue on each life-year and to compare that value to its cost of production (ie,
he CER).
The economists have used such VSL evaluations to assign a monetary value to
he increases in US life span since 1970 (about $2.8-$3.2 trillion per year), to the
eduction in heart disease mortality (about $1.5 trillion per year), and to a hypo-
hetical future 10% reduction in cardiac mortality (about $5.0-$5.7 trillion per
The Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 3 601
y
d
g
s
a
s
t
r
c
f
a
t
R
1
2
3
4
5
Statistics for the Rest of Us Starr, Wu, Grunkemeier
6
STA
TSear).3 These assessments and projections use the “top-
own” approach, the big picture. We, cardiothoracic sur-
eons, working in the engine room of the medical delivery
ystem, are in a position to apply these econometric methods in
“bottom-up” approach to assess the monetary value of our
urgical procedures.
The two companion papers4,5 published in this issue of
he Journal address the cost and value of aortic valve
eplacement, an increasingly performed procedure espe-
ially in the aged. These articles are presented as a stimulus
or our future long-term outcomes reporting to include cost
nd especially the economic value created by the high2006;131:412-7.
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